John Horton

Medicine · Health Sciences

38h-index21.6kcitations132works2.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(20), Glioma Diagnosis and Treatment(11), Breast Cancer Treatment Studies(11), Lymphoma Diagnosis and Treatment(8), Lung Cancer Treatments and Mutations(7)

Publications132 total

10 Oral: AKY-1189, a novel, first-in-class miniprotein radiopharmaceutical designed to deliver Actinium-225 (225Ac) to Nectin-4 expressing tumors with broad therapeutic applications in metastatic urothelial carcinoma (mUC) and other Nectin-4 expressing tumors
European Journal of Cancer·2024· 2 cited
Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population.
PubMed·2017· 35 citedOpen Access
P3.02b-042 Reduction in Peripheral Blood Cytokine Levels Observed in EGFR Mutant (EGFRm) Patients Treated with Erlotinib
Journal of Thoracic Oncology·2017· 1 cited
Abstract S3-06: Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017
Cancer Research·2016· 1 cited
Mechanisms of Functional Mitral Regurgitation in Ischemic Cardiomyopathy Determined by Transesophageal Echocardiography (from the Surgical Treatment for Ischemic Heart Failure Trial)
The American Journal of Cardiology·2013· 37 citedOpen Access
Letter from the Editor Emeritus
Cancer Control·2013Open Access
Characteristics of Oncology Clinical Trials
JAMA Internal Medicine·2013· 183 cited
Modest Increase in Peak VO <sub>2</sub> Is Related to Better Clinical Outcomes in Chronic Heart Failure Patients
Circulation Heart Failure·2012· 343 citedOpen Access
P2-08-02: Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017).
Cancer Research·2011· 2 cited
High-Grade Primary Pulmonary B Cell Lymphoma Presenting as a Necrotic Mass
Respiratory Care·2011· 1 citedOpen Access
Patient Education and Self-Advocacy: Questions and Responses on Pain Management
Journal of Pain & Palliative Care Pharmacotherapy·2009· 3 cited
SPECT myocardial perfusion imaging is a strong predictor of sudden cardiac death in patients with coronary artery disease
2008
Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular)
Europe PMC (PubMed Central)·2008· 6 cited
A single arm phase II trial of gemcitabine (G) and irinotecan (I) in metastatic breast cancer: Can localization of topoisomerase I (topo I) predict response to topo I inhibitors?
Journal of Clinical Oncology·2006· 2 cited
Is cytoplasmic localization of topoisomerase I (topo I) a mechanism of resistance for topo I inhibitors? Results from an NCCN sponsored phase II trial of gemcitabine and irinotecan in metastatic breast cancer.
Cancer Research·2006· 1 cited
Breast cancer in 2020: What can we expect?
Cancer Detection and Prevention·2006· 6 cited
A PHASE II DOSE-RANGING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN INDIA
American Journal of Tropical Medicine and Hygiene·2005· 137 citedOpen Access
Venous Thromboembolism and Cancer: Current Issues and Treatment Updates
Cancer Control·2005· 1 citedOpen Access
Venous Thrombotic Events in Cancer: The Bottom Line
Cancer Control·2005· 15 cited
Results of a planned efficacy and safety analysis for a National Comprehensive Cancer Network sponsored phase II study of gemcitabine and irinotecan (GI) in metastatic breast cancer (MBC)
Journal of Clinical Oncology·2005· 1 cited
page 1 of 7Next →

Frequent Co-authors

Kenneth B. Olson(8), Thomas J. Cunningham(6), J. Stuart Nelson(5), John C. Ruckdeschel(5), Paul P. Carbone(4), Charles P. Perlia(4), Robert W. Sponzo(4), Alan S. Weinstein(4), Richard H. Creech(3), Thomas E. Davis(3), Ediz Z. Ezdinli(3), Charles Scott(3), Andreas Fischbach(3), Diana F. Nelson(3), Chu H. Chang(3), David Schoenfeld(3), Paul B. Jacobsen(3), Lodovico Balducci(3), Gary H. Lyman(3), Bruce I. Shnider(3)